666 794

Cited 0 times in

공존이환(comorbidity)이 있는 암환자에서의 항암약물치료

DC Field Value Language
dc.contributor.author문용화-
dc.contributor.author정희철-
dc.date.accessioned2015-07-14T17:24:41Z-
dc.date.available2015-07-14T17:24:41Z-
dc.date.issued2004-
dc.identifier.issn1598-1320-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/112827-
dc.description.abstractThis report attempts to explain the (i) implications of comorbidity for research and practice in the fieldo of oncology, (ii) the approach for dosing of anti-cancer drugs in the presence of comorbidity, as an example of its clinical application, and finally (iii) the dosing guidelines for the anticancer drugs clinically active in gastric cancer in the presence of renal or liver dysfunction. This has resulted from the idea of approaching comorbidity in a systematic way and of integrating it with oncologic decisions. Various methods have been used to assess comorbidity. However, significant work remains to be done to analyze how various diseases combine to influence the oncologic outcome. The main end-point explored so far has been mortality, but a largely open challenge remains to correlate comorbidity with treatment tolerance and functional and quality of life, as well as to integrate it in clinical decision-making. Cancer chemotherapy in comorbidity should be considered as an example of the need for dose optimization in individual patients, and it should be determined by considering the basic principles of the pharmacokinetics and the pharmacodynamics of the agents. This review analyzes the available data on the pharmacokinetics and the toxicities of anti-cancer agents in the comorbidity population.-
dc.description.statementOfResponsibilityopen-
dc.format.extent59~74-
dc.relation.isPartOfJournal of the Korean Gastric Cancer Association (대한위암학회지)-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.title공존이환(comorbidity)이 있는 암환자에서의 항암약물치료-
dc.title.alternativeChemotherapy in Cancer Patients with Comorbidity-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthor정희철-
dc.contributor.googleauthor문용화-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01370-
dc.contributor.localIdA03794-
dc.relation.journalcodeJ01825-
dc.subject.keywordComorbidity-
dc.subject.keywordChemotherapy-
dc.contributor.alternativeNameMoon, Yong Wha-
dc.contributor.alternativeNameJeung, Hei Cheul-
dc.contributor.affiliatedAuthorMoon, Yong Wha-
dc.contributor.affiliatedAuthorJeung, Hei Cheul-
dc.rights.accessRightsfree-
dc.citation.volume4-
dc.citation.number2-
dc.citation.startPage59-
dc.citation.endPage74-
dc.identifier.bibliographicCitationJournal of the Korean Gastric Cancer Association (대한위암학회지), Vol.4(2) : 59-74, 2004-
dc.identifier.rimsid44540-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Research Institute (부설연구소) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.